| Austin Grace, PA | |
|
1501 S Yale St Ste 150, Flagstaff, AZ 86001-7337 | |
| (928) 527-4325 | |
| Not Available |
| Full Name | Austin Grace |
|---|---|
| Gender | Male |
| Speciality | Physician Assistant |
| Experience | 7 Years |
| Location | 1501 S Yale St Ste 150, Flagstaff, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679083364 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 6846 (Arizona) | Secondary |
| 363A00000X | Physician Assistant | 6846 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Wickenburg Community Hospital | Wickenburg, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Palo Verde Hematology Oncology Ltd | 6406840131 | 41 |
News Archive
New research led by UCD Conway Fellow, Professor Johan Ericsson has identified a key regulator of fat cell differentiation that may be a novel target for obesity drugs. The results of the research are published in the current edition of the scientific journal, Proceedings of the National Academy of Sciences (PNAS).
McKesson Corporation announced that its 2013 Pharmacy of the Year grand prize winner is Parkland Health Mart Pharmacy, located in Desloge, Missouri. Parkland Health Mart Pharmacy was honored in a special awards ceremony during the Opening General Session at the 2013 McKesson ideaShare conference.
About 80% of stroke survivors experience hemiparesis, which causes weakness or the inability to move one side of the body. Core stabilization exercise to improve postural stability and independent walking in chronic hemiparetic stroke patients could be enhanced by real-time video feedback, report researchers in Restorative Neurology and Neuroscience.
Investigators at Burnham Institute for Medical Research (Burnham) have identified novel cleavage sites for the enzyme caspase-3 (an enzyme that proteolytically cleaves target proteins). Using an advanced proteomic technique called N-terminomics, Guy Salvesen, Ph.D., professor and director of the Apoptosis and Cell Death Research program of Burnham's NCI-designated Cancer Center, and colleagues determined the cleavage sites on target proteins and found, contrary to previous understanding, that caspase-3 targets α-helices as well as unstructured loops.
Relypsa, Inc., today announced the initiation of patient enrollment in the PEARL-HF study, a Phase 2b clinical trial of the company's lead compound, RLY5016. A novel potassium binder designed for chronic use, RLY5016 is being evaluated in the prevention and treatment of hyperkalemia, for which there are no current satisfactory treatments.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Austin Grace, PA 1000 W Forest Meadows St Apt 266, Flagstaff, AZ 86001-2970 Ph: () - | Austin Grace, PA 1501 S Yale St Ste 150, Flagstaff, AZ 86001-7337 Ph: (928) 527-4325 |
News Archive
New research led by UCD Conway Fellow, Professor Johan Ericsson has identified a key regulator of fat cell differentiation that may be a novel target for obesity drugs. The results of the research are published in the current edition of the scientific journal, Proceedings of the National Academy of Sciences (PNAS).
McKesson Corporation announced that its 2013 Pharmacy of the Year grand prize winner is Parkland Health Mart Pharmacy, located in Desloge, Missouri. Parkland Health Mart Pharmacy was honored in a special awards ceremony during the Opening General Session at the 2013 McKesson ideaShare conference.
About 80% of stroke survivors experience hemiparesis, which causes weakness or the inability to move one side of the body. Core stabilization exercise to improve postural stability and independent walking in chronic hemiparetic stroke patients could be enhanced by real-time video feedback, report researchers in Restorative Neurology and Neuroscience.
Investigators at Burnham Institute for Medical Research (Burnham) have identified novel cleavage sites for the enzyme caspase-3 (an enzyme that proteolytically cleaves target proteins). Using an advanced proteomic technique called N-terminomics, Guy Salvesen, Ph.D., professor and director of the Apoptosis and Cell Death Research program of Burnham's NCI-designated Cancer Center, and colleagues determined the cleavage sites on target proteins and found, contrary to previous understanding, that caspase-3 targets α-helices as well as unstructured loops.
Relypsa, Inc., today announced the initiation of patient enrollment in the PEARL-HF study, a Phase 2b clinical trial of the company's lead compound, RLY5016. A novel potassium binder designed for chronic use, RLY5016 is being evaluated in the prevention and treatment of hyperkalemia, for which there are no current satisfactory treatments.
› Verified 4 days ago